BioInvent Reports Promising Progress in Phase I/lla Trial of Lead Program BI-1206 in Combination with Rituximab
- Tuesday, April 14, 2020, 7:03
- Finance
- Add a comment
LUND, Sweden, April 14, 2020 /PRNewswire/ — BioInvent International AB (“BioInvent” or the “Company”) (OMXS: BINV) today provides a preliminary insight into progress of its Phase I/IIa trial of BI-1206 in combination with rituximab for treatment of Non-Hodgkin Lymphoma (NHL). In the…
About the Author
adminasapcorp has written 41608 stories on this site.